ERIS Lifesciences Ltd

ERIS Lifesciences experienced a notable decline on February 10, 2025, following a three-day gain streak. The stock underperformed relative to its sector, despite remaining above key moving averages. Over the past month, it has shown resilience with an increase, contrasting with the broader market's modest performance.

ERIS Lifesciences has demonstrated strong performance in the Pharmaceuticals & Drugs sector, gaining 3.27% on February 7, 2025. The stock has shown a notable upward trend over the past three days, with a 20.93% return, and is trading above key moving averages, outperforming the broader market.

ERIS Lifesciences has demonstrated notable performance in the Pharmaceuticals & Drugs sector, achieving a significant return over the past two days. The stock has shown high volatility during trading, reaching an intraday high and maintaining a position above key moving averages, indicating a strong market presence.

ERIS Lifesciences experienced notable trading activity on February 5, 2025, with a significant intraday gain. The stock opened higher and reached a peak, outperforming the broader market. While it has shown modest growth over the past month, its moving averages present mixed signals for future performance.

ERIS Lifesciences experienced notable trading activity on February 5, 2025, with a significant intraday gain. The stock opened higher and reached a peak, outperforming the broader market. While it has shown modest growth over the past month, its moving averages present mixed signals for future performance.

ERIS Lifesciences has reported its financial results for the quarter ending December 2024, showcasing a significant year-on-year growth in net sales of 49.59%, totaling Rs 727.45 crore. However, the company experienced an 18.6% decline in Profit After Tax, alongside a 24.88% increase in interest expenses for the half-year period.

ERIS Lifesciences has faced significant challenges, with its stock declining 5.36% on January 27, 2025, and a total drop of 8.29% over two days. The company is trading below its moving averages and has seen a 14.68% decline over the past month, underperforming the broader market.

ERIS Lifesciences has experienced a revision in its score, reflecting recent market dynamics. Despite a decline in stock price and underperformance against the sector, the company maintains a strong position with moving averages surpassing key benchmarks. ERIS Lifesciences has been added to MarketsMOJO's list, indicating ongoing investor interest.

ERIS Lifesciences has recently achieved a significant milestone, reaching a 52-week high in stock price. Following this performance, MarketsMOJO has made a revision in its score for the stock. The company has consistently outperformed its sector and demonstrated strong returns, reinforcing its position in the pharmaceutical industry.

ERIS Lifesciences has been added to MarketsMOJO's list following a recent adjustment in its evaluation. The stock has demonstrated strong performance, achieving a new all-time high and consistently outperforming the sector and the Sensex. Investors are encouraged to monitor ERIS Lifesciences as it maintains its upward trajectory.

ERIS Lifesciences has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock has reached a 52-week high and has consistently outperformed its sector, showcasing robust gains over the past year and a positive trend across various moving averages.

ERIS Lifesciences has recently been added to MarketsMOJO's list following a revision in its score, reflecting the stock's strong performance. The company achieved a new all-time high, outperforming both its sector and the Sensex, indicating a positive trend in its market position and financial metrics.

ERIS Lifesciences has demonstrated a robust performance in the pharmaceutical sector, with recent adjustments in its evaluation reflecting positive market sentiment. The stock has been added to MarketsMOJO's list, highlighting its strong momentum and consistent gains, outperforming both its sector and the broader market.

ERIS Lifesciences, a midcap pharmaceutical company, saw a 6.52% increase in its stock price on November 25, 2024. The stock has been performing well, trading 3.54% below its 52-week high and outperforming the sector by 5.59%. With consecutive gains for the last 3 days and trading above its moving averages, ERIS Lifesciences shows strong potential in the market.

ERIS Lifesciences, a midcap pharmaceutical company, saw a 5.28% increase in its stock price on November 12, 2024, outperforming the sector by 3.04%. The stock has been on a consecutive gain for the last 3 days, currently trading higher than its moving averages. ERIS focuses on providing affordable medicines and has gained investor attention, but no future potential is mentioned.

ERIS Lifesciences, a midcap pharmaceutical company, has reported a flat performance in the quarter ending September 2024, with a score of 2 compared to -10 in the previous quarter. However, the company's net sales, operating cash flow, operating profit, and profit before tax have all shown positive trends. Some areas, such as increased interest cost and lower dividend payout ratio, require improvement. Investors are advised to hold their stock and monitor future performance.

On September 30th, 2024, ERIS Lifesciences, a midcap pharmaceutical company, saw a 5.08% increase in its stock, outperforming the sector by 5.74%. This follows three days of falling prices, suggesting a potential trend reversal. According to MarketsMOJO, the current stock call for ERIS Lifesciences is 'Hold', based on recent performance and market trends.

ERIS Lifesciences, a top pharmaceutical company in the largecap industry, saw a 3.4% rise in stock price on September 6th, 2024. According to MarketsMOJO, the stock is currently rated as 'Hold' and has been gaining for the past two days, hitting a new 52-week and all-time high. ERIS Lifesciences has consistently outperformed the market, showcasing its strong growth and stability in the pharmaceutical sector.

ERIS Lifesciences, a midcap pharmaceutical company, has reached a 52-week high on September 6th, 2024, with a 'Hold' call from MarketsMOJO. The stock has seen consecutive gains in the past two days, outperforming the sector by 2.55%. With a strong 1-year performance of 81.81%, ERIS Lifesciences is a leading player in the industry.